MedPath

Early Indicators of Chronic Rejection in Lung Transplant

Terminated
Conditions
Chronic Rejection in Lung Transplant
Cytokine Production in Bos Post Lung Transplant
Registration Number
NCT00449332
Lead Sponsor
University of Chicago
Brief Summary

The purpose of this research is to discover the different patterns of cytokine production in patients who may develop Bronchiolitis Obliterans Syndrome-0p (BOS-0p) which means ongoing rejection. This is an early indicator of chronic rejection in lung transplant recipients. These cytokines can be detected in the bronchoalveolar (lung) and tissue samples of lung transplant recipients.

Detailed Description

Lung transplant recipients are routinely followed in clinic every three months after the first year post-transplant. Spirometry with measurement of FEV1, FVC and FEF25-75 are obtained at each visit. In addition, lung transplant recipients undergo surveillance bronchoscopy at one, three, six, nine and twelve months. All bronchoscopy specimens that are obtained for this study will be obtained during bronchoscopies that were scheduled per the physician caring for the patient. An extra 90 cc of sterile solution will be instilled into bronchus and two extra transbronchial biopsies will be performed in addition to the routine bronchoscopic procedure. Routinely, 4-8 transbronchial biopsy samples are obtained from the transplanted lung. Two specimens will be randomly selected for study and the rest will undergo routine histopathologic study. The study biopsies will be set aside and processed. The study visits for this research will occur at the same time as standard of care post transplant visits. We will collect subject's history,demographic of subject's transplant data,donor procurement information, physical exam information, pregnancy tests,blood test and spirometry results from the visits mentioned above.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
120
Inclusion Criteria
  • Lung transplant recipients between the ages of 18 and 65 years old
  • All patients must be able to give written informed consent
Exclusion Criteria
  • Lung transplant recipients who are unable to undergo bronchoscopy
  • Lung transplant recipients who are unable to give informed consent

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
cytokines, chemokines and T cell subsets associated with BOS12/2013
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

The University of Chicago

🇺🇸

Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath